A Phase I Study of Oral ILX23-7553 [RO 237553] in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 May 2013
At a glance
- Drugs RO 237553 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2009 Actual end date (August 2002) added as reported by ClinicalTrials.gov record.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by clinicalTrials.gov record.
- 04 Oct 2005 New trial record.